WO2019224385A3 - Combined bispecific antibody and immuno-oncology therapies - Google Patents

Combined bispecific antibody and immuno-oncology therapies Download PDF

Info

Publication number
WO2019224385A3
WO2019224385A3 PCT/EP2019/063544 EP2019063544W WO2019224385A3 WO 2019224385 A3 WO2019224385 A3 WO 2019224385A3 EP 2019063544 W EP2019063544 W EP 2019063544W WO 2019224385 A3 WO2019224385 A3 WO 2019224385A3
Authority
WO
WIPO (PCT)
Prior art keywords
immuno
bispecific antibody
oncology therapies
combined
oncology
Prior art date
Application number
PCT/EP2019/063544
Other languages
French (fr)
Other versions
WO2019224385A2 (en
Inventor
Venkateshwar REDDY
Original Assignee
Glenmark Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals S.A. filed Critical Glenmark Pharmaceuticals S.A.
Publication of WO2019224385A2 publication Critical patent/WO2019224385A2/en
Publication of WO2019224385A3 publication Critical patent/WO2019224385A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to combinations of a T cell redirecting antibody and a second immuno-oncology or immunomodulatory agent to treat diseases, including cancer.
PCT/EP2019/063544 2018-05-24 2019-05-24 Combined bispecific antibody and immuno-oncology therapies WO2019224385A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18174133 2018-05-24
EP18174133.1 2018-05-24

Publications (2)

Publication Number Publication Date
WO2019224385A2 WO2019224385A2 (en) 2019-11-28
WO2019224385A3 true WO2019224385A3 (en) 2020-01-16

Family

ID=62386032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/063544 WO2019224385A2 (en) 2018-05-24 2019-05-24 Combined bispecific antibody and immuno-oncology therapies

Country Status (1)

Country Link
WO (1) WO2019224385A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3791931A1 (en) * 2019-09-13 2021-03-17 Ichnos Sciences SA Bispecific antibodies for the treatment of solid tumors
EP4136254A4 (en) * 2020-04-13 2024-05-22 Maddon Advisors LLC Ace2-targeted compositions and methods for treating covid-19
US20240084012A1 (en) * 2020-12-31 2024-03-14 Abvision, Inc. Anti-pd-1/cd47 bispecific antibody and use thereof
WO2024081602A2 (en) * 2022-10-11 2024-04-18 Maddon Advisors Llc Ace2-targeted compositions and methods for treating co0vid-19

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
WO2015149077A1 (en) * 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2017210058A1 (en) * 2016-06-01 2017-12-07 Ibc Pharmaceuticals, Inc. Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
WO2018057303A1 (en) * 2016-09-26 2018-03-29 Imclone Llc Combination therapy for cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
WO2015149077A1 (en) * 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2017210058A1 (en) * 2016-06-01 2017-12-07 Ibc Pharmaceuticals, Inc. Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
WO2018057303A1 (en) * 2016-09-26 2018-03-29 Imclone Llc Combination therapy for cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANDRES LOPEZ-ALBAITERO ET AL: "Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody", ONCOIMMUNOLOGY, vol. 6, no. 3, 4 March 2017 (2017-03-04), pages e1267891, XP055374515, DOI: 10.1080/2162402X.2016.1267891 *
BISWANATH MAJUMDER ET AL: "Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity", NATURE COMMUNICATIONS, vol. 6, 27 February 2015 (2015-02-27), pages 6169, XP055178650, DOI: 10.1038/ncomms7169 *
CHIEN-HSING CHANG ET AL: "Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells", CANCER RESEARCH, vol. 77, no. 19, 1 October 2017 (2017-10-01), US, pages 5384 - 5394, XP055542223, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-16-3431 *
JONATHAN BACK ET AL: "GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.", JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15_suppl, 20 May 2018 (2018-05-20), US, pages 12053 - 12053, XP055610900, ISSN: 0732-183X, DOI: 10.1200/JCO.2018.36.15_suppl.12053 *
L. G. LUM ET AL: "Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial", CLINICAL CANCER RESEARCH, vol. 21, no. 10, 15 May 2015 (2015-05-15), pages 2305 - 2314, XP055216347, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-2280 *
NCT03272334: "History of Changes for Study: NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47)", 31 August 2017 (2017-08-31), XP055611003, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03272334?V_1=View#StudyPageTop> [retrieved on 20190805] *
PIERRE MORETTI ET AL: "BEAT the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs From 23rd European Society for Animal Cell Technology (ESACT) Meeting: Better Cells for Better Background", BMC PROCEEDINGS, vol. 7 ( suppl.6), 23 June 2013 (2013-06-23), pages 1 - 3, XP055645478 *
REUSCH U ET AL: "Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model", CLINICAL CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 12, no. 1, 1 January 2006 (2006-01-01), pages 183 - 190, XP003017842, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-1855 *
SEUNG Y. CHU ET AL: "Immunotherapy with long-lived anti-CD38 x anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in Monkeys : a potential therapy for multiple myeloma", BLOOD, vol. 124, no. 21, 6 December 2014 (2014-12-06), US, pages 4727 - 4727, XP055645717, ISSN: 0006-4971, DOI: 10.1182/blood.V124.21.4727.4727 *
TAKUYA OSADA ET AL: "CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 64, no. 6, 1 June 2015 (2015-06-01), Berlin/Heidelberg, pages 677 - 688, XP055547201, ISSN: 0340-7004, DOI: 10.1007/s00262-015-1671-y *
YU LIN ET AL: "T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 145, no. 4, 23 February 2019 (2019-02-23), pages 941 - 956, XP036741197, ISSN: 0171-5216, [retrieved on 20190223], DOI: 10.1007/S00432-019-02867-6 *
Z. WU ET AL: "T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics", PHARMACOLOGY AND THERAPEUTICS., vol. 182, 1 February 2018 (2018-02-01), GB, pages 161 - 175, XP055636083, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2017.08.005 *

Also Published As

Publication number Publication date
WO2019224385A2 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
WO2019224385A3 (en) Combined bispecific antibody and immuno-oncology therapies
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
WO2018089508A3 (en) Anti-cd47 antibodies
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
WO2017152085A8 (en) Combination therapy with anti-cd73 antibodies
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
WO2016172726A9 (en) Modulators of ror1-ror2 binding
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2017049038A3 (en) Anti-cd115 antibodies
WO2019142149A3 (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2021005075A (en) Methods for treating castration-resistant and castration- sensitive prostate cancer.
WO2018134681A8 (en) Anti-tgf-beta antibodies and their use
WO2017214170A3 (en) Baff-r antibodies and uses thereof
EP3853257A4 (en) Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
MX2020008122A (en) Anti-pd-1 antibodies.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
WO2021055577A3 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
EP4039705A4 (en) Antibody targeting bcma, bispecific antibody, and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19728347

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19728347

Country of ref document: EP

Kind code of ref document: A2